Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.51 |
| ▸ | SHBG | P04278 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9862638 | 0.91 | ESR1 (0.49) | ESR1ESR2SHBGHSD17B1CYP19A1 | |
| SCHEMBL3649408 | 0.81 | SHBG (0.56) | ESR1ESR2SHBGHSD17B1HTR1A | |
| SCHEMBL3649497 | 0.79 | SHBG (0.71) | ESR1ESR2SHBGHSD17B1HTR1A | |
| SCHEMBL13875399 | 0.79 | SHBG (0.71) | ESR1ESR2SHBGHSD17B1HTR1A | |
| SCHEMBL13875379 | 0.78 | ESR1 (0.48) | ESR1ESR2SHBGHSD17B1CYP19A1 | |
| SCHEMBL13875376 | 0.78 | ESR1 (0.58) | ESR1ESR2 | |
| SCHEMBL4176612 | 0.78 | ESR1 (0.48) | ESR1ESR2SHBGHSD17B1CYP19A1 | |
| SCHEMBL4169468 | 0.78 | SHBG (0.56) | ESR1ESR2SHBG | |
| SCHEMBL9418172 | 0.78 | ESR1 (0.56) | ESR1ESR2CYP19A1 | |
| SCHEMBL30835166 | 0.77 | ESR1 (0.55) | ESR1ESR2SHBGHSD17B1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200962-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-06-30 | — | — | EP | claimed |
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | claimed |
| WO-2009047343-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-04-16 | — | — | WO | claimed |
| EP-2200962-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-06-30 | — | — | EP | disclosed |
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2009047343-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-04-16 | — | — | WO | disclosed |
| EP-2048126-A1 | Benzocycloheptane derivatives as selectively active oestrogens | Bayer Schering Pharma AG (DE) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | CYP19A1, HSD17B11, CYP21A2 | ESR1 4/4885ESR2 23/4885SHBG 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.